| 33.04 0.2 (0.61%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.6  |
1-year : | 46.26 |
| Resists | First : | 33.9 |
Second : | 39.6 |
| Pivot price | 32.87 |
|||
| Supports | First : | 32.69 |
Second : | 31.95 |
| MAs | MA(5) : | 32.92 |
MA(20) : | 32.86  |
| MA(100) : | 35.31 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 44.8 |
D(3) : | 45.7 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 38.79 | Low : | 23.69 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SNN ] has closed below upper band by 39.4%. Bollinger Bands are 57.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 33.09 - 33.21 | 33.21 - 33.31 |
| Low: | 32.32 - 32.48 | 32.48 - 32.61 |
| Close: | 32.81 - 33.05 | 33.05 - 33.24 |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Fri, 26 Dec 2025
'He's Been Very, Very Good': Terry Smith Praises Matt Campbell's Start As Staff Prepares For Bowl Game - Onward State
Fri, 26 Dec 2025
Marcia Carole Smith - Fraker Funeral Home, Inc.
Fri, 26 Dec 2025
Ohio promotes DC Hauser to replace fired Smith - ESPN
Fri, 26 Dec 2025
'Lion King' Broadway star Imani Dia Smith killed; boyfriend arrested - USA Today
Fri, 26 Dec 2025
Live updates: Terry Smith Pinstripe Bowl press conference - On3
Fri, 26 Dec 2025
Analysis: Vikings defense, inspired Harrison Smith deliver a Christmas spectacle - Star Tribune
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 424 (M) |
| Shares Float | 866 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 2,380 (K) |
| Shares Short P.Month | 2,440 (K) |
| EPS | 1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.32 |
| Profit Margin | 8.2 % |
| Operating Margin | 14.4 % |
| Return on Assets (ttm) | 5.8 % |
| Return on Equity (ttm) | 9.1 % |
| Qtrly Rev. Growth | 4.6 % |
| Gross Profit (p.s.) | 9.89 |
| Sales Per Share | 13.99 |
| EBITDA (p.s.) | 3.39 |
| Qtrly Earnings Growth | 35.9 % |
| Operating Cash Flow | 1,140 (M) |
| Levered Free Cash Flow | 701 (M) |
| PE Ratio | 29.5 |
| PEG Ratio | 0 |
| Price to Book value | 5.21 |
| Price to Sales | 2.36 |
| Price to Cash Flow | 12.3 |
| Dividend | 0.3 |
| Forward Dividend | 0 |
| Dividend Yield | 0.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|